Deal Diary

Welcome to Acquisition International’s Deal Diary, the place where we showcase exciting deals from across the globe. With each diary entry, we’ll be taking a comprehensive look at the inner workings of the deal in question and will be venturing behind the scenes to take a look at the dedicated professionals involved in ensuring its success.

Here you will discover the most active deal makers and a comprehensive catalogue of the transactions they have been involved with.

Tier 1: The Website - Go live worldwide within 24 hours!

Within 24 hours of booking, we'll upload your deal and company profile - including contact details and links to your homepage - right here on our site, putting you and your firm in front of
40,000 visitors every month!

You will, of course, get a full company bio, including your contact details and fully clickable links direct to your website, and to make sure the people who matter will be able to find every deal you and your firm have been involved in at the click of a button, all of the deals posted on the Deal Diary site are incredibly easy to search by firm name, individual name, sector or region. We even have an automatically updated deal leaderboard (right). 

Tier 2: The Newsletter - Direct to 108,000 subscribers!

Your involvement in the deal will be featured on our weekly Deal Round-Up newsletter,  published via email every Thursday to a global audience of  108,000. Your deal write-up will also include hyperlinked images and logos, taking readers straight to your homepage. That’s a potential 108,000 clicks every month!

Tier 3: The Publication - Sent to 108,000 people in 170 countries!

The deal and your involvement will appear in the Deal Diary section of our monthly magazine, distributed to 108,000 people in 170 countries around the world. This is where you can tell us all about the deal and how you made it happen, providing the perfect opportunity to shout about your firm’s experience, expertise and the great work you’ve been doing.

GO

Shakespeare Martineau Advise on RCapital Investment's in Summit and Hotelcare
August 27, 2015
Trowers & Hamlin Advise on Cygnet Healthcare Acquisition of Alpha Hospitals
August 27, 2015
Sparebanken Hedmark Advise on Procuritas Capital Investors Investment in Daldata
August 27, 2015
Allen & Overy Advise on AMP Capital & 3i Infrastructure's Acquisition of Esvagt
August 27, 2015
Grant Thornton UK LLP Advise on Safestay's Acquisition of Smart City Hostel
August 27, 2015
Trigon Advise on Public Consulting Group's Acquisition of Librus from Oresa Ventures
August 27, 2015
Ashurst Advise During Omers's acquisition of Environmental Resources Management
August 20, 2015
CMS Advise During Echo BV’s Acquisition of a Stake in Echo Investment
August 20, 2015
Baker & McKenzie Advise During Walmark's Acquisition of Pneumolan
August 20, 2015
JAC's Acquisition of NXP RF Power Business
August 20, 2015
Grant Thornton Advise Four Communications investment from BGF
August 20, 2015
Allen & Overy Advise During HIG European Capital Partners' Acquisition of Centros Unico
August 20, 2015
Taylor Wessing Advises THMMS's Acquisition of EliteMedianet
August 13, 2015
DLA Piper Advises Oakley Capital on Acquisition of Shares in Daisy
August 13, 2015
Skadden Advises NFP Acquisition of BWD
August 13, 2015
Aberdeen Asset Management Acquisition of Arden Asset Management
August 13, 2015
Milbank Advises ProSiebenSat.1 on Acquisition of Verivox from Oakley Capital
August 13, 2015
Gunner Cooke Advises on Statesman Travel Acquisition of Greaves Travel
August 13, 2015
McDermott Will & Emery Advises Biota's Acquisition of Anaconda Pharma
August 6, 2015
JP Morgan Advises Opko's Acquisition of Bio-Reference Laboratorie
August 6, 2015

McDermott Will & Emery Advises Biota's Acquisition of Anaconda Pharma

View Biography
Image

International law firm McDermott Will & Emery advised the shareholders of Anaconda Pharma on the sale of the company to Biota Pharmaceuticals.

Anaconda Pharma was formed in 2003 as a spin-out of the Institut Pasteur and is focused on the development of treatments against human papillomavirus (HPV) infections.   Under the agreement, all of Anaconda Pharma's shares will be acquired for shares of Biota common stock and $8 million in cash, subject to certain adjustments. Biota Pharmaceuticals, Inc. is a company focused on the discovery and development of products to treat serious viral respiratory infectious diseases.

Biota will fund the cash portion of the purchase price with cash on hand. Anaconda’s shareholders may earn up to $30 million if the company achieves certain clinical and regulatory milestones, in addition to a royalty.  The deal is expected to occur by the end of April 2015, subject to approval of the French Ministry of Finance and Economics and other customary conditions.

Anaconda Pharma's lead candidate is AP611074, a patented, direct-acting antiviral in development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis, both of which are caused by HPV types 6 and 11. Anaconda Pharma successfully completed a Phase 2a clinical trial of AP611074 5% gel demonstrating biological activity with a significant reduction in the surface area of condyloma while exhibiting favorable local skin tolerability.

Reflecting McDermott’s life science capabilities and global platform, Anaconda Pharma’s shareholders were represented by attorneys in McDermott’s Paris, New York and Washington DC offices, including Emmanuelle Trombe, Anthony Paronneau, Noëmie Fort, Antoine Vergnat, Christophe Jolk, Jilali Maazouz and Myrtille Lapuelle, Joel L. Rubinstein and Elliott Smith.

MORE...
Share this page:
Copyright Acquisition Intl. 2016